Connor, Clark & Lunn Investment Management (CC&L)’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-67	Closed	-$211K	–	1233
2021 Q2	$211K	Buy	+67	New	+$265K	﹤0.01%	908
2021 Q1	–	Sell	-72	Closed	-$411K	–	1104
2020 Q4	$411K	Buy	72 +16	+29%	+$101K	﹤0.01%	747
2020 Q3	$332K	Buy	+56	New	+$327K	﹤0.01%	779

Other funds holding YARW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s YARW Position: Q3 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q3 2021, closing a stake of 67 shares — an estimated $211K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in YARW in Q3 2020 and held it in 3 quarters. The position peaked at $411K in Q4 2020. 58 funds tracked by Wall St. Rank hold YARW as of Q3 2021.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 67 Yarrow Bioscience, Inc. Common Stock shares in Q3 2021, an estimated $211K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Yarrow Bioscience, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Yarrow Bioscience, Inc. Common Stock position peaked at $411K in Q4 2020.
58 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q3 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2021, filed 12 Nov 2021.